GSE140172 High-Throughput Kinetic Analysis of Fractional Killing

Contributors : Zintis Inde ; Giovanni C Forcina ; Kyle Denton ; Scott J DixonSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAnti-cancer drugs and other lethal agents can induce heterogeneous cell death responses in a population of cancer cells, a phenomenon referred to as fractional killing (FK). FK is often studied on a cell-by-cell basis in response to one or a limited number of stimuli. Here, we develop and validate methods to quantify FK in a high-throughput manner using population-level time-lapse measurements and mathematical modelling. Using this approach, we find that FK is highly variable over time and that the kinetics of this process can vary substantially by drug class and cell line. Focusing on FK induced by clinical candidate inhibitors of mitogen activated protein kinase kinase (MEK) 1/2, we find that MCL1 levels are be an important determinant of FK in some but not all cell lines and that generalizable molecular models of FK are rare. These studies lay the foundation for quantitative high-throughput analyses of FK.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Related Links:

Conditions:   Advanced Lung Non-Small Cell Carcinoma;   Metastatic Lung Non-Small Cell Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Sta ge IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8 Intervention:   Drug: Fluorin...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Families With Minor Children and One Parent Suffering From Cancer Intervention:   Other: F-SPOKE Sponsor:   RWTH Aachen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Malignant Neoplasm;   Locally Advanced Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Recurrent Malignant Neoplasm Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Prostate Cancer Intervention:   Drug: rhPSMA-7.3 (18F) Injection Sponsors:   Blue Earth Diagnostics;   Parexel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Prostate Cancer Intervention:   Drug: rhPSMA-7.3 (18F) Injection Sponsors:   Blue Earth Diagnostics;   Parexel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Occupational Therapy;   Cancer;   Dyspnea;   Rehabilitation Interventions:   Procedure: Comprehensive functional care plan;   Procedure: Traditional intervention without rehabilitation Sponsor:   University of Salamanca Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Prostate Cancer Intervention:   Drug: BP-C2 Sponsors:   Meddoc;   Meabco A/S;   Norwegian University of Life Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Malignant Neoplasm Interventions:   Drug: Fentanyl Sublingual Spray;   Drug: Morphine;   Other: Physical Performance Testing;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   D011471;   D064129;   D035683;   D009360;   D014408 Intervention:   Diagnostic Test: Periodic ARV7 and miRNA evaluation Sponsor:   Azienda Ospedaliero-Universitaria Careggi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Colon Cancer Intervention:   Combination Product: CAPECITABINE AND OXALIPLATIN Sponsor:   Universidad de León Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Genetics | Study